Brown Brothers Harriman & Co’s Maravai LifeSciences MRVI Stock Holding History

Brown Brothers Harriman & Co’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-56	Closed	-$2	–	1290
2021 Q4	$2	Hold	56	–	–	﹤0.01%	1082
2021 Q3	$3	Hold	56	–	–	﹤0.01%	1040
2021 Q2	$2	Hold	56	–	–	﹤0.01%	1079
2021 Q1	$2	Hold	56	–	–	﹤0.01%	1033
2020 Q4	$2K	Buy	+56	New	+$1.56K	﹤0.01%	1026

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Brown Brothers Harriman & Co's MRVI Position: Q1 2022 in Review

Brown Brothers Harriman & Co sold out of Maravai LifeSciences (MRVI) in Q1 2022, closing a stake of 56 shares — an estimated $2 sold.

Brown Brothers Harriman & Co first reported a position in MRVI in Q4 2020 and held it in 5 quarters. The position peaked at $2K in Q4 2020. 235 funds tracked by Wall St. Rank hold MRVI as of Q1 2022.

Brown Brothers Harriman & Co reported no remaining Maravai LifeSciences position as of Q1 2022 after selling out during the quarter.
Brown Brothers Harriman & Co sold 56 Maravai LifeSciences shares in Q1 2022, an estimated $2.
Brown Brothers Harriman & Co first reported a position in Maravai LifeSciences in Q4 2020 and held it in 5 quarters.
Brown Brothers Harriman & Co's Maravai LifeSciences position peaked at $2K in Q4 2020.
235 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2022.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2022, filed 13 May 2022.